This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Erenumab parenteral

Updated 2 Feb 2023 | Migraine prophylaxis


Injections of erenumab.

Drugs List

  • AIMOVIG PRE-FILLED PEN 140mg injection solution
  • AIMOVIG PRE-FILLED PEN 70mg injection solution
  • erenumab pre-filled pen 140mg injection solution
  • erenumab pre-filled pen 70mg injection solution
  • Therapeutic Indications


    Migraine (prophylaxis)

    Migraine prophylaxis in adults experiencing at least 4 migraine days per month.


    70mg every 4 weeks.
    Some patients may benefit from an increased dose of 140mg every 4 weeks.


    For subcutaneous injection only.

    Administered into the abdomen, thigh or outer area of the upper arm (the arm should only be used if administered by a person other than the patient).


    Children under 18 years

    Precautions and Warnings

    Decreased gastrointestinal motility
    Severe cardiovascular disorder

    Treatment to be initiated by specialist
    Contains polysorbate
    Needle cover contains a derivative of latex
    Avoid injection into broken or bruised skin
    Advise patient to report constipation
    Monitor for constipation; give laxatives as required
    Discontinue if an adequate response not achieved within 3 months
    Discontinue if significant constipation occurs, until resolved

    Response to treatment should be reviewed after 3 months and in those showing clinical benefit, at regular intervals thereafter.

    Constipation has been reported with the use of erenumab, the majority of cases are reported after the first dose of erenumab, other cases have also been reported later in the treatment. In most cases constipation resolved within three months. Severe constipation requiring hospitalisation have also been reported. Advise patient to report worsening constipation. Consider discontinuation if severe constipation occurs.

    Pregnancy and Lactation


    Use erenumab with caution during pregnancy.

    The manufacturer does not recommend using erenumab during pregnancy. At the time of writing there is limited published information regarding the use of erenumab during pregnancy. Potential risks are unknown.


    Use erenumab with caution in breastfeeding.

    The manufacturer advises caution if erenumab is used when breastfeeding. The presence of erenumab in human breast milk is unknown but due to its large molecular weight, transfer is not expected. Effects on exposed infants are unknown.

    Side Effects

    Development of neutralising antibodies
    Erythema at injection site
    Hypersensitivity reactions
    Injection site reactions
    Itching (injection site)
    Local pain (injection site)
    Muscle spasm


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2019

    Reference Sources

    Summary of Product Characteristics: Aimovig 70mg & 140mg solution for injection in pre-filled pen. Novartis Pharmaceuticals. Revised August 2020.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Erenumab Last revised: 03 December 2018
    Last accessed: 12 September 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.